Remove how-to-patent-in-europe-epo
article thumbnail

How the UPC and European Patents with Unitary Effect Reach Beyond Europe to the United States

IP Watchdog

The impact of the long-awaited launch of the Unified Patent Court (UPC) is hard to overstate. While litigators and patent portfolio managers are immediately feeling the impact in Europe, surprisingly, they should also expect an impact on information disclosure statement (IDS) strategy for U.S. patent applications.

article thumbnail

Building High-Quality Patent Portfolios in the United States and Europe: Part II – Software Patents

IP Watchdog

In Part I of this series, we discussed how patent portfolio managers should be careful when generating company-owned prior art or reviewing competitor prior art, and how a patent litigation or licensing campaign can be significantly hamstrung based on how the United States and Europe consider intervening prior art.

Patent 96
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

US Supreme Court decision in Amgen v Sanofi: The European Perspective

The IPKat

The US Supreme Court recently ruled in the high profile Amgen versus Sanofi patent dispute. 2021 ), the Supreme Court found Amgen's function and epitope defined PCSK9 antibody patents to lack enablement ( Amgen Inc v Sanofi, No. The patents in dispute in Amgen v Sanofi defined a class of antibodies by their function and epitope.

article thumbnail

Book Review: A Practitioner’s Guide to European Patent Law (with a discount code)

The IPKat

This Kat is delighted to review “ A Practitioner’s Guide to European Patent Law: For National Practice and the Unified Patent Court ” (Hart Publishing, 2022, 664 pp.). non-infringement or that a patent is standard essential), and on FRAND (fair, reasonable and non-discriminatory) licensing. the Bolar exemption and exhaustion).

article thumbnail

The IPKat EPO Boards of Appeal (BA) Year in Review 2021

The IPKat

Following on from our IPKat EBA 2021 Year in Review , here is some more festive holiday reading on some of the important decisions to come out of the EPO Boards of Appeal this year. As the year draws to the close, the EPO has announced the Legal Boards of Appeal decision on whether an AI can be named as an inventor (J 8/20 and J 9/20).

Inventor 123
article thumbnail

Principals Moritz Ammelburg and Peter Fasse Author Managing IP Article “Coordinating Patent Prosecution in the U.S. and Europe”

Fish & Richardson Trademark & Copyright Thoughts

Moritz Ammelburg and Peter Fasse examine the patentability requirements and prosecution schemes in the US and Europe and how applicants can prepare applications that will best serve their needs in both jurisdictions. can significantly complicate the coordination of a global patent strategy. PDF copy available.

article thumbnail

No "German injunction gap" expedition in Abbott v Dexcom global diabetes battle, as Mr Justice Mellor expresses "some regret"

The IPKat

Merpel gives the "German injunction gap" factor some much needed side-eye After the end of what English and Welsh litigators call the Trinity term (aka end of the term before the Court breaks for the summer holidays), Mr Justice Mellor was working overtime to deliver two decisions. But no such luck for Abbott, " regret[tably] ".